These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37904277)
1. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap. Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277 [TBL] [Abstract][Full Text] [Related]
2. Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma. Koh J; Kim H; Moon KC; Lee C; Lee K; Ryu HS; Jung KC; Jeon YK Am J Surg Pathol; 2023 Feb; 47(2):183-193. PubMed ID: 36253891 [TBL] [Abstract][Full Text] [Related]
3. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications. Akbulut D; Whiting K; Teo MY; Tallman JE; Ozcan GG; Basar M; Jia L; Rammal R; Chen JF; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Mehra R; Baine M; Bochner BH; Pietzak EJ; Bajorin DF; Rosenberg JE; Iyer G; Solit DB; Reuter VE; Rekhtman N; Ostrovnaya I; Al-Ahmadie H Mod Pathol; 2024 Oct; 37(10):100557. PubMed ID: 38964503 [TBL] [Abstract][Full Text] [Related]
4. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Baine MK; Febres-Aldana CA; Chang JC; Jungbluth AA; Sethi S; Antonescu CR; Travis WD; Hsieh MS; Roh MS; Homer RJ; Ladanyi M; Egger JV; Lai WV; Rudin CM; Rekhtman N J Thorac Oncol; 2022 Sep; 17(9):1109-1121. PubMed ID: 35760287 [TBL] [Abstract][Full Text] [Related]
5. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities. Yamada Y; Belharazem-Vitacolonnna D; Bohnenberger H; Weiß C; Matsui N; Kriegsmann M; Kriegsmann K; Sinn P; Simon-Keller K; Hamilton G; Graeter T; Preissler G; Ott G; Schölch S; Nakajima N; Yoshizawa A; Haga H; Date H; Thomas RK; Petrini I; Giaccone G; Ströbel P; Marx A Cell Death Dis; 2022 Nov; 13(11):979. PubMed ID: 36402755 [TBL] [Abstract][Full Text] [Related]
6. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888 [TBL] [Abstract][Full Text] [Related]
7. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma. Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008 [TBL] [Abstract][Full Text] [Related]
8. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388 [TBL] [Abstract][Full Text] [Related]
9. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma. Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429 [TBL] [Abstract][Full Text] [Related]
10. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086 [TBL] [Abstract][Full Text] [Related]
11. Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall. Inoue H; Matsushima J; Kobayashi S; Sairenchi T; Hirata H; Chida M; Ota S; Ban S; Matsumura Y Int J Surg Pathol; 2022 Apr; 30(2):151-159. PubMed ID: 34913369 [TBL] [Abstract][Full Text] [Related]
12. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer. Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936 [TBL] [Abstract][Full Text] [Related]
13. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721 [TBL] [Abstract][Full Text] [Related]
14. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer. Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179 [TBL] [Abstract][Full Text] [Related]
15. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038 [TBL] [Abstract][Full Text] [Related]
16. TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. Miyagawa-Hayashino A; Okada S; Takeda-Miyata N; Takashima Y; Yamada T; Takemura Y; Uchino J; Inoue M; Takayama K; Konishi E Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):313-320. PubMed ID: 33031101 [TBL] [Abstract][Full Text] [Related]
17. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor. Kim G; Kim M; Nam EJ; Lee JY; Park E Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832 [TBL] [Abstract][Full Text] [Related]
18. High-grade neuroendocrine carcinoma of the lung: comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma. Sun L; Sakurai S; Sano T; Hironaka M; Kawashima O; Nakajima T Pathol Int; 2009 Aug; 59(8):522-9. PubMed ID: 19627535 [TBL] [Abstract][Full Text] [Related]
19. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC? Kawai H; Matsuoka R; Ito T; Matsubara D Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340 [TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]